The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation

Biochemical Pharmacology

Volumn 86, Issue 6, 2013, Pages 770-781

  Wiemer, Andrew J ^a   Wernimont, Sarah A ^b   Cung, Thai D ^b   Bennin, David A ^b   Beggs, Hilary E ^c   Huttenlocher, Anna ^b,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Focal adhesion kinase; Integrin; PF 562,271; RhoA; T cell receptor

Indexed keywords

FOCAL ADHESION KINASE INHIBITOR; IONOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PF 562271; PF 573228; PHORBOL 13 ACETATE 12 MYRISTATE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION;

EID: 84885180497     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.024     Document Type: Article

References (36)

1. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nature Reviews Cancer 2005; 5: 505-15. (Pubitemid 40942827)
2. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasisinatransgenic mouse model ofhuman breast cancer. The American Journal of Pathology 2008; 173: 1551-65.
3. PylayevaY, GillenKM, GeraldW, BeggsHE, Reichardt LF, Ras - Giancotti FG. PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. The Journal of Clinical Investigation 2009; 119: 252-66.
4. Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, et al. Focal adhesion kinase as potential target for cancer therapy. Oncology Reports 2009; 22: 973-9 [review].
5. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Research 2008; 68: 1935-44. (Pubitemid 351416580)
6. Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, Swanson T, et al. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biology & Therapy 2009; 8: 856-65.
7. Bagi CM, Roberts GW, Andresen CJ. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer 2008; 112: 2313-21. (Pubitemid 351628644)
8. Schultze A, Fiedler W. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs 2010; 19: 777-88.
9. Siu LL, Burris HA, Mileshkin L, Camidge DR, Rischin D, Chen EX, et al. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. In: 2007 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 2007; 25: 3527.
10. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. Journal of Clinical Oncology 2012; 30: 1527-33.
11. Bacon KB, Szabo MC, Yssel H, Bolen JB, Schall TJ. RANTES induces tyrosine kinase activity of stably complexed p125(FAK) and ZAP-70 in human T cells. The Journal of Experimental Medicine 1996; 184: 873-82.
12. Tabassam FH, Umehara H, Huang JY, Gouda S, Kono T, Okazaki T, et al. Beta2-integrin, LFA-1, and TCR/CD3 synergistically induce tyrosine phosphorylation of focal adhesion kinase (pp125(FAK)) in PHA-activated T cells. Cellular Immunology 1999; 193: 179-84. (Pubitemid 29228363)
13. Berg NN, Ostergaard HL. T cell receptor engagement induces tyrosine phosphorylation of FAK and Pyk2 and their association with Lck. Journal of Immunology 1997; 159: 1753-7. (Pubitemid 127484161)
14. Maguire JE, Danahey KM, Burkly LC, van Seventer GA. T cell receptor- and beta 1 integrin-mediated signals synergize to induce tyrosine phosphorylation of focal adhesion kinase (pp125FAK) in human T cells. The Journal of Experimental Medicine 1995; 182: 2079-90.
15. Ilic D, Furuta Y, Suda T, Atsumi T, Fujimoto J, Ikawa Y, et al. Focal adhesion kinase is not essential for in vitro and in vivo differentiation of ES cells. Biochemical and Biophysical Research Communications 1995; 209: 300-9.
16. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP, et al. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 10740-45. (Pubitemid 37140098)
17. Beinke S, Phee H, Clingan JM, Schlessinger J, Matloubian M, Weiss A. Prolinerich tyrosine kinase-2 is critical for CD8 T-cell short-lived effector fate. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 16234-39.
18. Wang M, Zhang W, Zhang Y. Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Hybridoma (Larchmt) 2009; 28: 333-9.
19. Simonson WTN, Franco SJ, Huttenlocher A. Talin1 regulates TCR-mediated LFA-1 function. Journal of Immunology 2006; 177: 7707-14. (Pubitemid 44846286)
20. Beggs HE, Schahin-Reed D, Zang KL, Goebbels S, Nave KA, Gorski J, et al. FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron 2003; 40: 501-14. (Pubitemid 37494700)
21. Wernimont SA, Wiemer AJ, Bennin DA, Monkley SJ, Ludwig T, Critchley DR, et al. Contact-dependent T cell activation and T cell stopping require talin1. Journal of Immunology 2011; 187: 6256-67.
22. Wiemer AJ, Lokuta MA, Surfus JC, Wernimont SA, Huttenlocher A. Calpain inhibition impairs TNF-alpha-mediated neutrophil adhesion, arrest and oxidative burst. Molecular Immunology 2010; 47: 894-902.
23. Van Wauwe JP, De Mey JR, Goossens JG. OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. Journal of Immunology 1980; 124: 2708-13. (Pubitemid 10116043)
24. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313: 1972-5. (Pubitemid 44498006)
25. Wiemer AJ, WernimontS, HuttenlocherA. Live imaging of LFA-1-dependent T-cell motility and stop signals. Methods in Molecular Biology 2012; 757: 191-204.
26. Wernimont SA, Legate KR, Simonson WT, Fassler R, Huttenlocher A. PIPKI gamma 90 negatively regulates LFA-1-mediated adhesion and activation in antigen-induced CD4+ T cells. Journal of Immunology 2010; 185: 4714-23.
27. Wiemer AJ, Hegde S, Gumperz JE, Huttenlocher A. A live imaging cell motility screen identifies prostaglandin E2 as a T cell stop signal antagonist. Journal of Immunology 2011; 187: 3663-70.
28. Katagiri K, Hattori M, Minato N, Kinashi T. Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Molecular and Cellular Biology 2002; 22: 1001-15. (Pubitemid 34094838)
29. Collins M, TremblayM, Chapman N, Curtiss M, Rothman PB, The Houtman JCD. T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402 and 580 occurs via a distinct mechanism than other receptor systems. Journal of Leukocyte Biology 2010; 87: 691-701.
30. Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Reviews 2009; 28: 35-49.
31. Qian D, Lev S, van Oers NS, Dikic I, Schlessinger J, Weiss A. Tyrosine phosphorylation of Pyk2 is selectively regulated by Fyn during TCR signaling. The Journal of Experimental Medicine 1997; 185: 1253-9. (Pubitemid 27172906)
32. Heasman SJ, Carlin LM, Cox S, Ng T, Ridley AJ. Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. The Journal of Cell Biology 2010; 190: 553-63.
33. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 2004; 427: 154-9. (Pubitemid 38094955)
34. Pasvolsky R, Grabovsky V, Giagulli C, Shulman Z, Shamri R, Feigelson SW, et al. RhoA is involved in LFA-1 extension triggered by CXCL12 but not in a novel outside-in LFA-1 activation facilitated by CXCL9. Journal of Immunology 2008; 180: 2815-23.
35. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, et al. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006; 25: 5969-84. (Pubitemid 44477291)
36. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-77. (Pubitemid 351213423)